Table 1 Association between BCAR1 staining and prostate cancer clinical characteristics
From: High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer
Parameter | BCAR1 (%) | |||||
|---|---|---|---|---|---|---|
| Â | N evaluable | Negative | Weak | Moderate | Strong | P value |
All cancers | 9472 | 22.4 | 15.9 | 23.2 | 38.5 | Â |
Tumor stage | ||||||
 pT2 | 6170 | 23.7 | 15.9 | 23.1 | 37.4 | 0.0082 |
 pT3a | 2138 | 20.4 | 16.1 | 24.2 | 39.3 | |
 pT3b-pT4 | 1160 | 19.5 | 15.6 | 21.7 | 43.2 | |
Gleason score | ||||||
 ≤ 3 + 3 | 2186 | 27.2 | 19.0 | 23.1 | 30.8 | < 0.0001 |
 3 + 4 | 5133 | 21.9 | 14.9 | 23.5 | 39.8 | |
 3 + 4 Tertiary 5 | 345 | 22.9 | 14.5 | 23.8 | 38.8 | |
 4 + 3 | 893 | 18.4 | 17.6 | 21.7 | 42.3 | |
 4 + 3 Tertiary 5 | 464 | 15.1 | 14.4 | 22.4 | 48.1 | |
 ≥ 4 + 4 | 445 | 20.9 | 11.7 | 23.2 | 44.3 | |
Lymph node metastasis | ||||||
 N0 | 5262 | 20.9 | 16.1 | 23.2 | 40.0 | <0.0001 |
 N+ | 494 | 21.3 | 12.8 | 21.5 | 44.5 | |
Preoperative PSA level (ng/ml) | ||||||
 < 4 | 1480 | 16.9 | 15.0 | 24.0 | 44.1 | <0.0001 |
 4–10 | 5475 | 21.6 | 15.9 | 23.5 | 39.0 | |
 10–20 | 1817 | 26.0 | 15.9 | 22.5 | 35.6 | |
 > 20 | 638 | 32.1 | 17.6 | 19.0 | 31.4 | |
Surgical margin | ||||||
 Negative | 7566 | 22.1 | 15.8 | 23.3 | 38.8 | <0.0001 |
 Positive | 1794 | 23.4 | 16.2 | 22.9 | 37.6 | |